Pulmostics

Pulmostics is a private health technology and diagnostics company developing non-invasive breath-analysis systems for early cancer detection. Its lead product, BreathSense 1000, is a portable device designed to detect volatile organic compound patterns in exhaled breath associated with malignancy, with an initial focus on breast cancer and additional work in lung cancer. The company positions its platform as a low-cost, rapid, painless alternative or complement to conventional screening methods such as mammography. Pulmostics appears to operate primarily as a medtech diagnostics developer rather than a therapeutics company, and its public materials emphasize clinical validation, biomarker analysis, and point-of-care deployment.